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Abstract
Paraphilias are intense urges or behaviors involving non-normative sexual interests. The newly 
approved diagnostic criteria in the DSM-5 have established that, while paraphilias should not be 
regarded as inherently pathological, they ought to be qualified as paraphilic disorders if resulting 
in distress, impairment or harm to the affected individual or others. Recent evidence documents 
that both phenomena can emerge as relatively uncommon iatrogenic consequences in Parkinson's 
disease (PD) patients. To outline the clinical characteristics of paraphilias and paraphilic disorders 
in PD patients, we summarized the available evidence on these phenomena. The review 
encompasses all studies on paraphilias in PD patients identified by a search on the Pubmed and 
Scopus online databases through May 2014. Twenty-two case reports on a total of 31 PD patients 
with paraphilias and/or paraphilic disorders were identified. These phenomena were typically 
associated with dopaminomimetic treatment (with a mean levodopa-equivalent daily dose of 
1303±823 mg/day) in male patients with motor complications, young age at PD onset and long 
disease duration. Paraphilias were highly concomitant with impulse-control disorders and/or 
dopamine dysregulation syndrome. Although evidence on paraphilias and paraphilic disorders in 
PD patients remains anecdotal, available data point to these phenomena as likely sequelae of high-
dose dopaminomimetic treatment. Accordingly, the intensity of paraphilic urges is typically 
attenuated by the reduction of dopaminomimetic doses, sometimes in association with atypical 
antipsychotics. Failure to recognize paraphilic disorders may significantly impair the relational 
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functioning of the affected PD patients. Practitioners should routinely inquire about paraphilias 
during their clinical assessment of PD patients.
Keywords
Parkinson's disease; Paraphilias; Paraphilic disorders; Impulse control disorders; Dopamine 
dysregulation syndrome
Introduction
Converging lines of evidence have shown that, in a subset of Parkinson's disease (PD) 
patients, administration of dopaminomimetic agents induces a broad range of abnormal 
sexual manifestations1, including hypersexuality2,3 and paraphilias.
While a final consensus is yet to be reached on the definition of hypersexual behaviors 
(described in the ICD-10 as satyriasis in men and nymphomania in women), these 
manifestations are generally intended as characterized by maladaptive preoccupation with 
(or indulgence in) erotic acts and sexual thoughts. Paraphilias are also described as recurrent 
urges, fantasies or behaviors, resulting in intense sexual arousal; in contrast with 
hypersexuality, however, these responses are typically evoked by non-normative (and 
sometimes illicit) sexual stimuli. Given the flexibility of sexual norms across time and 
different cultural milieux, the exact definition of paraphilias and their classification as 
pathological conditions remains a highly contentious issue. In response to these concerns, 
the fifth edition of the American Psychiatric Association's Diagnostic and Statistical Manual 
of Mental Disorders (DSM-5)4 has recently provided a final definition of paraphilias as “any 
intense and persistent sexual interest other than a sexual interest in general stimulation or 
preparatory fondling with phenotypically normal, physically mature, consenting human 
partners”. The classification of paraphilias as atypical, yet not inherently pathological 
behaviors, contrasts with that of paraphilic disorders, in which the presence of deviant, 
maladaptive erotic urges results in a significant threat to the psychological and physical 
well-being of the affected individual or others. Specifically, the current diagnosis of 
paraphilic disorders requires that: 1) the patient experiences personal distress over persistent 
(at least 6 months) and troubling sexual fantasies, urges or behaviors (and not simply 
distress from society's disapproval), and that 2) such behaviors entail distress, injury or 
death of another individuals, or involve unwilling persons or persons unable to give legal 
consent.4
While neurologists have become increasingly aware of the highly negative impact of sexual 
dysfunctions and paraphilic disorders in PD patients, the lack of systematic diagnostic 
descriptions of these conditions limits the ability to prevent or attenuate their impact. Thus, 
the present study was aimed at conducting a review of the available peer-reviewed 
publications on case reports, and highlighting the current evidence on PD-associated 
paraphilias, including their clinical phenomenology, concurrence with other drug-induced 
complications, as well as therapeutic prospects.
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We conducted a detailed Internet-based literature search on all available articles on 
paraphilic behaviors and disorders in PD through May 2014, using PubMed and Scopus 
databases. Paraphilia and paraphilic disorders were defined in line with the DSM-5 criteria4. 
The DSM-5 lists eight specific types of paraphilic disorders, namely exhibitionistic disorder; 
fetishistic disorder; frotteuristic disorder; pedophilic disorder; sexual masochism disorder; 
sexual sadism disorder; transvestic disorder; and voyeuristic disorder. A ninth residual 
category, described as other specified paraphilic disorders, includes telephone-scatologic 
disorder, necrophilic disorder, zoophilic disorder, coprophilic disorder, klismaphilic disorder 
urophilic disorder, etc. Given that the definitions of the DSM5 do not correspond with the 
legal definition of sex offending, the literature research was also extended to other cases of 
PD associated with illegal behaviors such as rape, sex offence, sex abuse, sexual crimes etc.
For each patient, the following criteria were recorded: gender; age at onset of paraphilias; 
age at onset of PD; disease duration; dopaminomimetic drugs used; total levodopa 
equivalent daily dose (LEDD); the number and type of paraphilias; presence or absence of 
other hypersexual behaviors, sex offences and psychiatric comorbid entities, including 
dopamine dysregulation syndrome (DDS) and impulse control disorders (ICDs).
LEDDs were either based on the values reported in the articles, or calculated as previously 
described5, with the following formula: Levodopa dose + levodopa dose×1/3 if on 
entacapone + bromocriptine (mg)×10 + cabergoline or pramipexole (mg) × 67 + ropinirole 
or rotigotine (mg) × 20 + pergolide (mg) × 100 + apomorphine (mg) × 8.
Characteristics of Paraphilias in PD
Twenty-two case reports on a total of 31 PD patients affected by paraphilias and/or 
paraphilic disorders were identified3, 6-26. The individual characteristics of each patient are 
reported in Table 1. Patients were all males, with the exception of two females. Paraphilias 
included exhibitionism, frotteurism, pedophilia, sexual masochism, transvestism and 
voyeurism, as well as other specified paraphilias such as telephone scatology, zoophilia, 
klismaphilia, etc. None of the studies measured and/or estimated the prevalence of 
paraphilia and/or paraphilic disorders in PD. Exhibitionism was the most commonly 
described paraphilia (10 cases), followed by tranvestism (6 cases), zoophilia (5 cases), 
voyeurism and pedophilia (4 cases each). In five patients, multiple paraphilias were 
reported. Mean age at onset of paraphilias was 57.5 ±12.6 years, mean age at PD onset was 
45.5±12.2 years, while mean duration of PD at onset of paraphilic behaviors was 12.2 ± 8.5 
years, ranging from 3 to 37 years. Eighteen patients were classified as early-onset PD 
patients with disease onset at or before age 45.
In all patients, paraphilias were developed following treatment with dopaminomimetic 
agents; moreover, three of them were also under concomitant treatment with Deep Brain 
Stimulation (DBS). Levodopa treatment was reported in at least 27 patients; dopamine 
agonists were used by 22 patients, including pergolide (8), pramipexole (6), ropinirole (4), 
bromocriptine (3) and lisuride (1). Six patients were treated with the monoamine oxidase 
(MAO) B inhibitor selegiline. Five of these patients were on levodopa monotherapy 
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(although two of them were under concomitant DBS), while only a single patient was 
assuming a dopamine agonist in monotherapy. Mean LEDD was 1303±823 mg/day, with at 
least nine patients taking more than 1500 mg daily.
Two patients underwent a previous pallidotomy and other two patients underwent a previous 
unilateral thalamotomy several years before developing paraphilic behaviors and/or 
disorders. A search for comorbidity issues revealed that, although not every article reported 
the presence of motor complications, a large proportion of the patients (Table 1) was also 
affected by motor fluctuations and dyskinesias. In eight patients, paraphilic behavior was 
accompanied by at least another ICD or punding. Nine patients were affected by dopamine 
dysregulation syndrome. Clinical history of presence of previous premorbid paraphilic 
symptoms was reported in 3 patients.
Pharmacological management of paraphilic disorders in PD patients was mainly based on 
the reduction in the dose of dopaminergic medications (23 patients). The employment of 
atypical neuroleptic drugs, often in association with dopaminergic treatment reduction, was 
reportedly useful in 13 patients, with satisfactory control of the disorder in a large proportion 
of patients. However, at least eight cases were brought to court with penal consequences. 
Cognitive or learning deficits were reported only in three patients (7, 11 and 30).
Discussion
To date, this is the most detailed review of the clinical features and correlates of paraphilias 
in PD. The results of our systematic review indicate that aberrant sexual behaviors in PD 
may include paraphilic behaviors and/or disorders such as exhibitionism, frotteurism, 
pedophilia, sexual masochism, transvestism and voyeurism, as well as other specified types 
of paraphilias such as telephone scatology, zoophilia, klismaphilia, etc. Given that the 
nosological distinction between paraphilias and paraphilic disorders was formally introduced 
only in 2013, it is sometimes difficult to retrospectively discern and define the pathological 
nature of the manifestations reported in the relevant literature. Nevertheless, most case 
reports underscored the egodystonic nature of paraphilias in PD, and described how these 
phenomena resulted in distress as well as social and functional impairments, thereby 
meeting the main diagnostic criteria for paraphilic disorders.
The under-reporting of paraphilias in PD patients limits potential comparisons with non-
normative sexual behaviors in the general population27-30. Nevertheless, our results indicate 
that iatrogenic and idiopathic paraphilias may share a number of critical features. First, three 
of the paraphilias most commonly described in PD patients (exhibitionism, transvestism and 
voyeurism) overlap with the most frequent sexual deviances in the general population. 
Second, in both conditions, paraphilic behaviors are highly concurrent with mental 
disorders31-34. Third, these phenomena are predominantly observed in male individuals, 
although some female cases have also been reported35-36.
Similarly to previous data on PD-associated hypersexuality37, paraphilic behaviors and 
disorders are more likely encountered in patients with younger-onset PD. The average age of 
PD onset is reportedly lower in patients affected by paraphilias (45.5 ± 12.2 years) than in 
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those with hypersexuality38 (50.2 ± 3.0 yrs). The low age of onset for paraphilic disorders 
may reflect the influence of different neurobiological or genetic conditions. It should be 
noted, however, that the inception of paraphilias was typically observed after an average of 
10 years from PD onset, in a stage in which PD motor complications become typical and 
may require higher doses of dopaminomimetic therapies. All PD patients who developed 
paraphilias were treated with levodopa (in monotherapy for 15% of the reported cases) or, 
less frequently, with dopamine receptor agonists (in monotherapy for 5% of the reported 
cases). Interestingly, also three patients under concomitant DBS developed paraphilic 
disorders. Thus, unlike ICDs, the development of aberrant sexual behaviors in PD does not 
appear to be tightly associated with the use of direct dopamine receptor agonists39-40.
In particular, the high comorbidity rate between DDS and paraphilic disorders suggests that 
the latter may be triggered by states of excessive activation of dopamine receptors 
consequent to very high doses of dopamine-replacement therapies (DRTs). This possibility 
is supported by the observation that most paraphilic behaviors reportedly ceased following 
dose reduction of DRTs3,7,8,11,12,14,15,17-19, 21,23-25. Of note, Nielsen and colleagues showed 
that these conditions ceased after withdrawal of dopaminergic drugs and resumed soon after 
DRT reinstatement12. However, the use of lower doses of dopaminomimetics did not result 
in a relapse of paraphilias, suggesting a specific relation of these conditions with high doses 
of DRTs12. This perspective is suggested by the efficacy of dopamine receptor antagonists 
with intermediate potency (such as atypical antipsychotics) in the management of these 
disorders.
In all cases of paraphilic behaviors associated with dopamimetics, symptom severity and/or 
pervasiveness was attenuated reduced by tapering down the dosage of these drugs or using 
dopaminergic antagonists. However, this treatment typically resulted in the exacerbation of 
PD manifestations. Notably, the only two cases in which paraphilic behaviors developed 
after DBS alone were not responsive to any pharmacological intervention; however, both 
patients had a history of drug dependence and, more importantly, had developed addiction to 
levodopa (with features of DDS) before and after neurosurgery. This complicated clinical 
scenario may have contributed to the development of treatment-refractory paraphilic 
manifestations; thus, the specific etiological role of DBS vis-à-vis these phenomena remains 
unclear. It is worth noting that, in one of these patients, sexually deviant fantasies were 
present before surgery, but were acted upon only after DBS, suggesting that the full 
expression of the paraphilic behavior may have been facilitated by the improvement of 
motor symptoms.
Whereas paraphilic behaviors in PD have been only described in the past few years - 
following the recognition that these entities affected 3% of all PD patients41-, hypersexuality 
was one of the earliest neuropsychiatric complications described in PD, with the first report 
dating to 196942. The most typical hypersexual behaviors induced by dopaminergic 
treatments in PD encompass excessive requests for sex from a spouse or a partner, increased 
interest in pornography, compulsive masturbation, etc. Similar sequelae have also been 
observed in patients receiving dopaminergic agonists for other conditions, such as restless 
leg syndrome and hyperprolactinemia due to pituitary dysfunction43-46.
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Although the relationship between dopamine signaling and the regulation of sexual behavior 
and urges is quite complex, hypersexuality and paraphilias may be the phenotypical 
expressions of different degrees of a common pathophysiological process. Accordingly, 
Voon et al.38 have included paraphilic behaviors in the spectrum of pathological 
hypersexuality associated to PD treatment. Indeed, both hypersexuality and paraphilias have 
been associated with agonists for D2/D3 dopamine receptors, such as pramipexole, 
ropinirole and pergolide10. This background suggests that, in some predisposed individuals, 
paraphilias may arise as the epiphenomena of an underlying impulsivity disorder 
characterized by sexual compulsivity and hypersexuality47, which may be compounded by 
dysfunctions of the frontal lobe48,49. Future neuropsychological and brain-imaging studies 
on PD patients affected by paraphilic disorders are warranted to understand the 
neurobiological bases and relationship of hypersexuality and paraphilias.
An important aspect of paraphilias concerns the mechanisms supporting the preference of 
non-normative targets for sexual arousal within the sphere of hypersexuality. It is well 
established that, among the general population, the enactment of erotic fantasies is generally 
limited, in view of cultural and moral constraints. Similarly, it is conceivable that a subgroup 
of PD patients may have sexual fantasies related to paraphilic preferences. In some of these 
patients, the shift from fantasy to behavioral manifestation may be due to high doses of 
dopamine-replacement therapies, likely in combination with concurrent biological 
predispositions. In addition to the existence of genetic vulnerability and premorbid 
personality traits, the individual susceptibility of a patient is largely influenced by ethno-
cultural and moral convictions, and can be precipitated by specific environmental 
contingencies. For instance, one of our patients exhibited paraphilic behaviors following his 
wife's death, as he was reportedly unable to have regular sexual intercourse18. Future studies 
with large populations of PD patients will be required to examine these complex interactions 
among genetic, environmental and pharmacological variables with respect to the incidence 
of paraphilic disorders.
Neurobiological bases of paraphilic behaviors and disorders in PD
The available data on the pharmacological modifications of paraphilic behaviors and 
disorders in PD can provide critical elements of insights to elucidate the neurobiological 
bases of these manifestations; these mechanisms, however, remain largely speculative. In 
consideration of the key role of nucleus accumbens in reward, it is possible that the 
excessive dopaminergic stimulation in this brain region may reflect a dysregulated 
recruitment of dopaminergic signaling pathways in this region50. An abnormal stimulation 
of this region has also been described in patients with DDS and is in agreement with the 
“neural sensitization” theory, which posits that the intermittent administration of 
dopaminomimetic agents may lead to neuronal sensitization of the mesolimbic 
dopaminergic system51-52. The chronic stimulation of dopamine receptors by DRTs has 
been postulated to lead to receptor hypersensitivity as the basis for these behavioral side 
effects15,50. According to Robinson and Berridge's incentive sensitization theory, 
progressive and persistent neuroadaptations induced in dopamine projections to the 
accumbens-related circuitry are closely related to compulsive drug use53,54. More recently, a 
PET study in PD patients affected by a compulsive medication use, showed an increased 
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ventral striatal dopamine release in response to an acute levodopa challenge, thus suggesting 
a crucial neuronal sensitization of such chronic levodopa use in this particular class of 
vulnerable individuals55.
It is conceivable that, similarly to DDS, overuse of dopaminergic agents could result in 
paraphilic behaviors by driving aberrant “novelty seeking” behaviors and excessive risk 
taking, or promoting disinhibition mechanism in control pathways15. Taken together, these 
data suggest that an excessive load of dopaminergic drugs could overtake the classical 
features of hypersexuality and lead to the expression of paraphilic disorders.
In addition to the accumbal involvement, other dopaminergic pathways may be involved in 
the genesis of paraphilic behaviors. For example, dopamine may increase sexual functions 
by reducing the secretion of prolactin, which exerts a major inhibitory function on sexual 
functions19,56. Furthermore, nigral dopaminergic projections are known to govern the 
activity of the medial preoptic area (MPOA) and paraventricular nucleus (PVN) of the 
hypothalamus, which are known to regulate libido and masculine sexual behavior57-59. 
Specifically, dopaminergic drugs may enhance sexual responses by increasing oxytocin 
release from the PVN60.
In addition to dopamine, paraphilic disorders in the general population have been associated 
with changes in other neurochemical factors, including serotonin and androgens. 
Accordingly, the therapy of these conditions is often based on serotonin reuptake inhibitors, 
antiandrogens and GnRH analogues, among others61.
Conclusions
Paraphilic disorders can lead to harmful conduct against themselves, their partners or others, 
sometimes resulting in criminal actions, such as in the case of pedophilia61. Indeed, a wealth 
of reports highlight the potentially devastating psychological, social, and/or legal, 
consequences of paraphilic disorders, including pedophilic, frotteuristic and exhibitionistic 
disorders in PD patients6,7,18,20,21. An interesting issue related to paraphilic disorders 
revolves around the question as to whether DRT-treated individuals should be considered 
responsible for harmful or criminal behaviors related to their erotic urges. Irrespective of 
these bioethical issues, the presence of premorbid signs for these disorders should be 
adequately investigated and monitored since early stages of PD. Once paraphilic disorders 
are suspected, dosage readjustments for antiparkinsonian drugs should always be 
considered. Future prospective and multicentric studies will hopefully provide improved 
diagnostic tools for the early detection of paraphilic behaviors in PD, as well as the 
identification of susceptibility factors and the quantification of the incidence and prevalence 
of these conditions.
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